Long-term safety and secondary efficacy endpoints in the ENGOT-OV16/NOVA phase III trial of niraparib in recurrent ovarian cancer

Ursula Matulonis; Jørn Herrstedt; Amit Oza; Sven Mahner; Andrés Redondo; Dominique Berton; Jonathan Berek; Bente Lund; Frederik Marmé; Antonio González-Martín; Anna Tinker; Jonathan Ledermann; Benedict Benigno; Gabriel Lindahl; Nicoletta Colombo; Yong Li; Divya Gupta; Bradley Monk; Mansoor Mirza

doi:10.1016/S0090-8258(21)00693-4

Long-term safety and secondary efficacy endpoints in the ENGOT-OV16/NOVA phase III trial of niraparib in recurrent ovarian cancer

Ursula Matulonis, Jørn Herrstedt, Amit Oza, Sven Mahner, Andrés Redondo, Dominique Berton, Jonathan Berek, Bente Lund, Frederik Marmé, Antonio González-Martín, Anna Tinker, Jonathan Ledermann, Benedict Benigno, Gabriel Lindahl, Nicoletta Colombo, Yong Li, Divya Gupta, Bradley Monk, Mansoor Mirza

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

Original language	English
Article number	37
Journal	Gynecologic Oncology
Volume	162
Issue number	Suppl. 1
Pages (from-to)	S24-S25
Number of pages	2
ISSN	0090-8258
DOIs	https://doi.org/10.1016/S0090-8258(21)00693-4
Publication status	Published - 2021
Event	52nd Annual Meeting on Women's Cancer - Virtual Duration: 20 Mar 2021 → 23 Mar 2021

Conference

Conference	52nd Annual Meeting on Women's Cancer
Location	Virtual
Period	20/03/2021 → 23/03/2021

Access to Document

10.1016/S0090-8258(21)00693-4

https://www.sciencedirect.com/science/article/pii/S0090825821006934

AUB Link

Search for the material in Aalborg University Library's search engine

Cite this

Matulonis, U., Herrstedt, J., Oza, A., Mahner, S., Redondo, A., Berton, D., Berek, J., Lund, B., Marmé, F., González-Martín, A., Tinker, A., Ledermann, J., Benigno, B., Lindahl, G., Colombo, N., Li, Y., Gupta, D., Monk, B., & Mirza, M. (2021). Long-term safety and secondary efficacy endpoints in the ENGOT-OV16/NOVA phase III trial of niraparib in recurrent ovarian cancer. Gynecologic Oncology, 162(Suppl. 1), S24-S25. Article 37. https://doi.org/10.1016/S0090-8258(21)00693-4

@article{bedc7928434242709fd765a6dfe6dd33,

title = "Long-term safety and secondary efficacy endpoints in the ENGOT-OV16/NOVA phase III trial of niraparib in recurrent ovarian cancer",

author = "Ursula Matulonis and J{\o}rn Herrstedt and Amit Oza and Sven Mahner and Andr{\'e}s Redondo and Dominique Berton and Jonathan Berek and Bente Lund and Frederik Marm{\'e} and Antonio Gonz{\'a}lez-Mart{\'i}n and Anna Tinker and Jonathan Ledermann and Benedict Benigno and Gabriel Lindahl and Nicoletta Colombo and Yong Li and Divya Gupta and Bradley Monk and Mansoor Mirza",

year = "2021",

doi = "10.1016/S0090-8258(21)00693-4",

language = "English",

volume = "162",

pages = "S24--S25",

journal = "Gynecologic Oncology",

issn = "0090-8258",

publisher = "Academic Press",

number = "Suppl. 1",

note = "52nd Annual Meeting on Women's Cancer ; Conference date: 20-03-2021 Through 23-03-2021",

}

Matulonis, U, Herrstedt, J, Oza, A, Mahner, S, Redondo, A, Berton, D, Berek, J, Lund, B, Marmé, F, González-Martín, A, Tinker, A, Ledermann, J, Benigno, B, Lindahl, G, Colombo, N, Li, Y, Gupta, D, Monk, B & Mirza, M 2021, 'Long-term safety and secondary efficacy endpoints in the ENGOT-OV16/NOVA phase III trial of niraparib in recurrent ovarian cancer', Gynecologic Oncology, vol. 162, no. Suppl. 1, 37, pp. S24-S25. https://doi.org/10.1016/S0090-8258(21)00693-4

TY - ABST

T1 - Long-term safety and secondary efficacy endpoints in the ENGOT-OV16/NOVA phase III trial of niraparib in recurrent ovarian cancer

AU - Matulonis, Ursula

AU - Herrstedt, Jørn

AU - Oza, Amit

AU - Mahner, Sven

AU - Redondo, Andrés

AU - Berton, Dominique

AU - Berek, Jonathan

AU - Lund, Bente

AU - Marmé, Frederik

AU - González-Martín, Antonio

AU - Tinker, Anna

AU - Ledermann, Jonathan

AU - Benigno, Benedict

AU - Lindahl, Gabriel

AU - Colombo, Nicoletta

AU - Li, Yong

AU - Gupta, Divya

AU - Monk, Bradley

AU - Mirza, Mansoor

PY - 2021

Y1 - 2021

U2 - 10.1016/S0090-8258(21)00693-4

DO - 10.1016/S0090-8258(21)00693-4

M3 - Conference abstract in journal

SN - 0090-8258

VL - 162

SP - S24-S25

JO - Gynecologic Oncology

JF - Gynecologic Oncology

IS - Suppl. 1

M1 - 37

T2 - 52nd Annual Meeting on Women's Cancer

Y2 - 20 March 2021 through 23 March 2021

ER -